Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary GSK announced the $11 billion acquisition of Nuvalent on June 9, 2026, gaining two experimental lung cancer drugs under FDA review. Zidesamtinib targets ROS1-positive NSCLC; neladalkib targets ALK-positive NSCLC.
Summary Incyte agreed to acquire Vega Therapeutics for $1.25 billion upfront on June 8, 2026, gaining VGA039, a subcutaneous monthly injection for von Willebrand disease (VWD), in Phase 3 testing.
On 9 June 2026, the European Commission published the first Joint Clinical Assessment (JCA) under the EU HTA Regulation. The drug assessed was tovorafenib (Ojemda), an oral RAF inhibitor for
Summary Roche announced a $700 million upfront collaboration with Nurix Therapeutics on June 8, 2026, to codevelop bexobrutideg, a BTK protein degrader, for blood cancers including CLL and autoimmune conditions.
Executive Summary During May 2026, MARA issued 14 new rating actions across hepatology, oncology, neurology, immunology, psychiatry, infectious diseases, pediatrics, and gynecology. The distribution was concentrated in the middle reimbursement-risk
We recently completed a MARA Rating for a treatment for Barth syndrome — a rare, life-threatening disease that affects young men and has no established disease-modifying therapy. The randomized trial
We have just published a MARA Rating for a treatment for schizophrenia and bipolar disorder. The clinical question payers must answer is: what does this drug do, in these patients,
We have just published a MARA Rating for an obesity treatment that has not yet completed Phase 3 trials. The Phase 2 data answered one question clearly: can this drug
Summary Servier agreed on June 1 to acquire sevasemten from Edgewise Therapeutics for up to $2.7 billion. The drug targets two forms of muscular dystrophy: Duchenne (DMD) and Becker (BMD).
We recently completed a MARA Rating for a treatment for a kidney disease that can progress to kidney failure over time. The phase 3 trial answered one question clearly: does